The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement

Authors: Vasilios G. Athyros, Theodore K. Alexandrides, Helen Bilianou, Εvangelos Cholongitas, Michael Doumas, Emmanuel S. Ganotakis, John Goudevenos, Moses Elisaf, Georgios Germanidis, Όλγα Γιουλεμέ, Asterios Karagiannis, Charalambos Karvounis, Niki Katsiki, Vasilios Kotsis, Jannis Kountouras, Evangelos Liberopoulos, Christos Pitsavos, Stergios Polyzos, Lοukianos S. Rallidis, Dimitrios Richter, Απόστολος Τσάπας, Alexandros D. Tselepis, Konstantinos Tsioufis, Κωνσταντίνος Τζιόμαλος, Themistoklis Tzotzas, Themistoklis G. Vasiliadis, Charalambos Vlachopoulos, Dimitri P. Mikhailidis, Christos S. Mantzoros - Metabolism 2017 cited by 251